IFNA1 and myeloid sarcoma: In the OPERA I and II trials, the cumulative proportion of patients with 24-week CDW at week 96 was 7.6% in MS patients treated with ocrelizumab compared to 12% in those receiving IFN, with HR of 0.60 (95% CI 0.43 – 0.84; p=0.003) (59).